Rosuvastatin: winner in the statin wars, patients' health notwithstanding
BMJ2015Vol. 350(mar17 4), pp. h1388–h1388
Citations Over TimeTop 18% of 2015 papers
Abstract
More is spent in the US on rosuvastatin than any other statin. Yet the evidence of its health benefits has always been weak and there is growing evidence of harmful side effects. Sidney Wolfe explains why he thinks the drug should have been withdrawn and why it should not be used
Related Papers
- → Rosuvastatin: winner in the statin wars, patients' health notwithstanding(2015)13 cited
- → Impact of the JUPITER Trial on Statin Prescribing for Primary Prevention(2013)5 cited
- → Effects of Rosuvastatin on Low-Density Lipoprotein Cholesterol and Plasma Lipids in Asian Patients with Hypercholesterolemia(2009)4 cited
- Is a statin a statin?(2001)
- High-Dose Statin Therapy by Rosuvastatin Reduced Small-Dense LDL and MDA-LDL: The High-Dose Statin Therapy with Rosuvastatin for Lipid-lowing (SARD) Trial(2015)